Ortin Global Limited

NSEI:ORTINGLOBE Stock Report

Market Cap: ₹149.5m

Ortin Global Past Earnings Performance

Past criteria checks 0/6

Ortin Global's earnings have been declining at an average annual rate of -67%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 52.6% per year.

Key information

-67.0%

Earnings growth rate

-63.8%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate-52.6%
Return on equity-334.1%
Net Margin-1,380.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention Today

Jan 24
Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention Today

Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Dec 27
Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Nov 30
Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Sep 15
Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Revenue & Expenses Breakdown

How Ortin Global makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:ORTINGLOBE Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245-7530
30 Jun 247-8240
31 Mar 2421-8060
31 Dec 2334-4180
30 Sep 2344-990
30 Jun 2350480
31 Mar 2360-190
31 Dec 2269-3100
30 Sep 2274-9140
30 Jun 2291-9120
31 Mar 2282-4100
31 Dec 21-1,931-19-280
30 Sep 21-1,427-12-160
30 Jun 21-685900
31 Mar 21829140
31 Dec 202,79346680
30 Sep 202,81623590
30 Jun 202,355-6550
31 Mar 201,974-6580
31 Dec 191,721-5500
30 Sep 191,61910490
30 Jun 191,7518450
31 Mar 191,67813430
31 Dec 181,650-2390
30 Sep 181,3411370
30 Jun 1899013340
31 Mar 187977340
31 Dec 177030340
30 Sep 17650-5350
30 Jun 17414-4340
31 Mar 176195340
31 Dec 166492330
30 Sep 166419310
30 Jun 1662412290
31 Mar 166298290
31 Dec 1560710380
30 Sep 1556910370
30 Jun 155879360
31 Mar 156049240
31 Dec 1446712400
30 Sep 1451312420
30 Jun 1461712410
31 Mar 1467112410
31 Dec 137243410

Quality Earnings: ORTINGLOBE is currently unprofitable.

Growing Profit Margin: ORTINGLOBE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ORTINGLOBE is unprofitable, and losses have increased over the past 5 years at a rate of 67% per year.

Accelerating Growth: Unable to compare ORTINGLOBE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORTINGLOBE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.4%).


Return on Equity

High ROE: ORTINGLOBE has a negative Return on Equity (-334.09%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:39
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ortin Global Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution